达帕格利弗洛辛通过增强线粒体功能和减少氧化应激,对棕酸盐诱导的管状上皮细胞产生保护作用
Tingting Ding1, Mingzhu Song2, Sihong Wang1
1Department of Endocrinology, Xuancheng People's Hospital, Xuancheng 242000, Anhui Province, China.
Journal of diabetes and its complications
|December 14, 2024
概括
达帕格利弗洛辛 (DAPA) 是一种SGLT2抑制剂,通过改善线粒体功能和减少氧化应激,保护细胞免受损伤. 这为治疗糖尿病病提供了新的治疗见解.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- -葡萄糖共载体2 (SGLT2) 抑制剂在糖尿病病中提供了除了葡萄糖控制之外的器官保护.
- 帕尔米特诱导的损伤模型是管状上皮细胞 (HK-2),模仿糖尿病状况.
研究的目的:
- 调查达帕格利弗洛辛 (DAPA) 对棕酸盐诱导的HK-2细胞损伤的保护作用.
- 专注于DAPA对线粒体功能和糖尿病病中氧化应激的影响.
主要方法:
- 用棕酸盐治疗的HK-2细胞,并与DAPA联合治疗.
- 评估了细胞活力,反应性氧物种 (ROS),线粒体膜潜力,甲 (MDA) 和超氧化物脱酶 (SOD).
- 通过西方斑点分析了亡 (Bax,Cytochrome C) 和自 (LC3,Beclin-1) 标记物;通过电子显微镜检查了线粒体形态.
主要成果:
- DAPA显著增加了细胞活力,并恢复了线粒体膜的潜力.
- DAPA降低了ROS和MDA水平,同时增加了SOD表达.
- DAPA逆转了palmitate诱导的亡和调节的自,改善了线粒体形态学.
结论:
- 达帕格利弗洛辛通过增强线粒体功能和减少氧化应激减轻管损伤.
- 通过这些机制,DAPA在治疗糖尿病病方面表现出治疗潜力.
- 这些发现为SGLT2抑制剂的保护作用提供了新的见解.
关键词:
达帕格利弗洛辛 (Dapagliflozin) 是一种糖尿病脏病 糖尿病脏病在HK-2细胞中,线粒体功能障碍 线粒体功能障碍氧化应激是一种氧化应激.棕酸盐是一种棕酸盐.这是一种SGLT2抑制剂.更多相关视频
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
Renal Drug Excretion: Tubular Secretion
121
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
121
Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
Drug Elimination by Renal Route: Tubular Secretion
2.1K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.1K


